Australia · Delayed Price · Currency is AUD CSL Limited Company Description
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants.
The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments.
The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology.
The company’s therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines.
It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease.
The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery.
CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
| Country | Australia |
| Founded | 1916 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29,000 |
| CEO | Gordon Naylor |
Contact Details
Address: 655 Elizabeth Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9389 1911 |
| Website | csl.com |
Stock Details
| Ticker Symbol | CSL |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| ISIN Number | AU000000CSL8 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gordon Naylor BEng (Hons), C.P.A., DipCompSc, M.B.A. | Chief Executive Officer, MD and Director |
| Ken Lim | Chief Financial Officer |
| Dr. Mary Oates Ph.D. | Executive Vice President and Chief Operating Officer |
| Mark Dehring | Head of Investor Relations |
| Gregory Boss B.S., BS(Hons), J.D. | Executive Vice President of Legal and Group General Counsel |
| Dr. William Mezzanotte M.D., M.P.H. | Chief Medical Officer, Executive Vice President and Head of Research and Development |